Applied Therapeutics Inc. (APLT),
a clinical-stage biopharmaceutical company developing a pipeline of
novel drug candidates against validated molecular targets in indications
of high unmet medical need, today announced the Company will give an
oral presentation of data at the American Society of Human Genetics
(ASHG) 2019 Annual Meeting in Houston (October 15-19) on AT-007, a
central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI)
in Phase 1/2 development for treatment of Galactosemia. In addition, the
Company will host an ASHG Educational Symposium featuring a panel of
Galactosemia experts.
https://finance.yahoo.com/news/applied-therapeutics-present-data-highlighting-110000624.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.